Table of Content

1 Attenuated Vaccine for Human Rabies Market Overview
1.1 Product Overview and Scope of Attenuated Vaccine for Human Rabies
1.2 Attenuated Vaccine for Human Rabies Segment by Type
1.2.1 Global Attenuated Vaccine for Human Rabies Market Value Comparison by Type (2024-2034)
1.2.2 Vero Cell
1.2.3 Human Diploid Cell
1.3 Attenuated Vaccine for Human Rabies Segment by Application
1.3.1 Global Attenuated Vaccine for Human Rabies Market Value by Application: (2024-2034)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Attenuated Vaccine for Human Rabies Market Size Estimates and Forecasts
1.4.1 Global Attenuated Vaccine for Human Rabies Revenue 2024-2034
1.4.2 Global Attenuated Vaccine for Human Rabies Sales 2024-2034
1.4.3 Global Attenuated Vaccine for Human Rabies Market Average Price (2024-2034)
1.5 Assumptions and Limitations
2 Attenuated Vaccine for Human Rabies Market Competition by Manufacturers
2.1 Global Attenuated Vaccine for Human Rabies Sales Market Share by Manufacturers (2024-2024)
2.2 Global Attenuated Vaccine for Human Rabies Revenue Market Share by Manufacturers (2024-2024)
2.3 Global Attenuated Vaccine for Human Rabies Average Price by Manufacturers (2024-2024)
2.4 Global Attenuated Vaccine for Human Rabies Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Attenuated Vaccine for Human Rabies, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Attenuated Vaccine for Human Rabies, Product Type & Application
2.7 Attenuated Vaccine for Human Rabies Market Competitive Situation and Trends
2.7.1 Attenuated Vaccine for Human Rabies Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Attenuated Vaccine for Human Rabies Players Market Share by Revenue
2.7.3 Global Attenuated Vaccine for Human Rabies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Attenuated Vaccine for Human Rabies Retrospective Market Scenario by Region
3.1 Global Attenuated Vaccine for Human Rabies Market Size by Region: 2024 Versus 2022 Versus 2034
3.2 Global Attenuated Vaccine for Human Rabies Global Attenuated Vaccine for Human Rabies Sales by Region: 2024-2034
3.2.1 Global Attenuated Vaccine for Human Rabies Sales by Region: 2024-2024
3.2.2 Global Attenuated Vaccine for Human Rabies Sales by Region: 2024-2034
3.3 Global Attenuated Vaccine for Human Rabies Global Attenuated Vaccine for Human Rabies Revenue by Region: 2024-2034
3.3.1 Global Attenuated Vaccine for Human Rabies Revenue by Region: 2024-2024
3.3.2 Global Attenuated Vaccine for Human Rabies Revenue by Region: 2024-2034
3.4 North America Attenuated Vaccine for Human Rabies Market Facts & Figures by Country
3.4.1 North America Attenuated Vaccine for Human Rabies Market Size by Country: 2024 VS 2022 VS 2034
3.4.2 North America Attenuated Vaccine for Human Rabies Sales by Country (2024-2034)
3.4.3 North America Attenuated Vaccine for Human Rabies Revenue by Country (2024-2034)
3.4.4 United States
3.4.5 Canada
3.5 Europe Attenuated Vaccine for Human Rabies Market Facts & Figures by Country
3.5.1 Europe Attenuated Vaccine for Human Rabies Market Size by Country: 2024 VS 2022 VS 2034
3.5.2 Europe Attenuated Vaccine for Human Rabies Sales by Country (2024-2034)
3.5.3 Europe Attenuated Vaccine for Human Rabies Revenue by Country (2024-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Attenuated Vaccine for Human Rabies Market Facts & Figures by Country
3.6.1 Asia Pacific Attenuated Vaccine for Human Rabies Market Size by Country: 2024 VS 2022 VS 2034
3.6.2 Asia Pacific Attenuated Vaccine for Human Rabies Sales by Country (2024-2034)
3.6.3 Asia Pacific Attenuated Vaccine for Human Rabies Revenue by Country (2024-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Attenuated Vaccine for Human Rabies Market Facts & Figures by Country
3.7.1 Latin America Attenuated Vaccine for Human Rabies Market Size by Country: 2024 VS 2022 VS 2034
3.7.2 Latin America Attenuated Vaccine for Human Rabies Sales by Country (2024-2034)
3.7.3 Latin America Attenuated Vaccine for Human Rabies Revenue by Country (2024-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Attenuated Vaccine for Human Rabies Market Facts & Figures by Country
3.8.1 Middle East and Africa Attenuated Vaccine for Human Rabies Market Size by Country: 2024 VS 2022 VS 2034
3.8.2 Middle East and Africa Attenuated Vaccine for Human Rabies Sales by Country (2024-2034)
3.8.3 Middle East and Africa Attenuated Vaccine for Human Rabies Revenue by Country (2024-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Attenuated Vaccine for Human Rabies Sales by Type (2024-2034)
4.1.1 Global Attenuated Vaccine for Human Rabies Sales by Type (2024-2024)
4.1.2 Global Attenuated Vaccine for Human Rabies Sales by Type (2024-2034)
4.1.3 Global Attenuated Vaccine for Human Rabies Sales Market Share by Type (2024-2034)
4.2 Global Attenuated Vaccine for Human Rabies Revenue by Type (2024-2034)
4.2.1 Global Attenuated Vaccine for Human Rabies Revenue by Type (2024-2024)
4.2.2 Global Attenuated Vaccine for Human Rabies Revenue by Type (2024-2034)
4.2.3 Global Attenuated Vaccine for Human Rabies Revenue Market Share by Type (2024-2034)
4.3 Global Attenuated Vaccine for Human Rabies Price by Type (2024-2034)
5 Segment by Application
5.1 Global Attenuated Vaccine for Human Rabies Sales by Application (2024-2034)
5.1.1 Global Attenuated Vaccine for Human Rabies Sales by Application (2024-2024)
5.1.2 Global Attenuated Vaccine for Human Rabies Sales by Application (2024-2034)
5.1.3 Global Attenuated Vaccine for Human Rabies Sales Market Share by Application (2024-2034)
5.2 Global Attenuated Vaccine for Human Rabies Revenue by Application (2024-2034)
5.2.1 Global Attenuated Vaccine for Human Rabies Revenue by Application (2024-2024)
5.2.2 Global Attenuated Vaccine for Human Rabies Revenue by Application (2024-2034)
5.2.3 Global Attenuated Vaccine for Human Rabies Revenue Market Share by Application (2024-2034)
5.3 Global Attenuated Vaccine for Human Rabies Price by Application (2024-2034)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Corporation Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2024-2024)
6.1.4 AstraZeneca Attenuated Vaccine for Human Rabies Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 GlaxoSmithKline
6.2.1 GlaxoSmithKline Corporation Information
6.2.2 GlaxoSmithKline Description and Business Overview
6.2.3 GlaxoSmithKline Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2024-2024)
6.2.4 GlaxoSmithKline Attenuated Vaccine for Human Rabies Product Portfolio
6.2.5 GlaxoSmithKline Recent Developments/Updates
6.3 Merck & Co Inc
6.3.1 Merck & Co Inc Corporation Information
6.3.2 Merck & Co Inc Description and Business Overview
6.3.3 Merck & Co Inc Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2024-2024)
6.3.4 Merck & Co Inc Attenuated Vaccine for Human Rabies Product Portfolio
6.3.5 Merck & Co Inc Recent Developments/Updates
6.4 Sanofi Pasteur, Inc
6.4.1 Sanofi Pasteur, Inc Corporation Information
6.4.2 Sanofi Pasteur, Inc Description and Business Overview
6.4.3 Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2024-2024)
6.4.4 Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Product Portfolio
6.4.5 Sanofi Pasteur, Inc Recent Developments/Updates
6.5 Cadila Pharmaceuticals Ltd
6.5.1 Cadila Pharmaceuticals Ltd Corporation Information
6.5.2 Cadila Pharmaceuticals Ltd Description and Business Overview
6.5.3 Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2024-2024)
6.5.4 Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Product Portfolio
6.5.5 Cadila Pharmaceuticals Ltd Recent Developments/Updates
6.6 Novartis AG
6.6.1 Novartis AG Corporation Information
6.6.2 Novartis AG Description and Business Overview
6.6.3 Novartis AG Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2024-2024)
6.6.4 Novartis AG Attenuated Vaccine for Human Rabies Product Portfolio
6.6.5 Novartis AG Recent Developments/Updates
6.7 Pfizer Inc
6.6.1 Pfizer Inc Corporation Information
6.6.2 Pfizer Inc Description and Business Overview
6.6.3 Pfizer Inc Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2024-2024)
6.4.4 Pfizer Inc Attenuated Vaccine for Human Rabies Product Portfolio
6.7.5 Pfizer Inc Recent Developments/Updates
6.8 Liaoning Yisheng Biopharmaceutical Co., Ltd
6.8.1 Liaoning Yisheng Biopharmaceutical Co., Ltd Corporation Information
6.8.2 Liaoning Yisheng Biopharmaceutical Co., Ltd Description and Business Overview
6.8.3 Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2024-2024)
6.8.4 Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
6.8.5 Liaoning Yisheng Biopharmaceutical Co., Ltd Recent Developments/Updates
6.9 Lanzhou Institute of Biological Products Co., Ltd
6.9.1 Lanzhou Institute of Biological Products Co., Ltd Corporation Information
6.9.2 Lanzhou Institute of Biological Products Co., Ltd Description and Business Overview
6.9.3 Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2024-2024)
6.9.4 Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
6.9.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments/Updates
6.10 Changchun Zhuoyi Biological Co., Ltd
6.10.1 Changchun Zhuoyi Biological Co., Ltd Corporation Information
6.10.2 Changchun Zhuoyi Biological Co., Ltd Description and Business Overview
6.10.3 Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2024-2024)
6.10.4 Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
6.10.5 Changchun Zhuoyi Biological Co., Ltd Recent Developments/Updates
6.11 Guangzhou Nuocheng Biological Products Co., Ltd
6.11.1 Guangzhou Nuocheng Biological Products Co., Ltd Corporation Information
6.11.2 Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Description and Business Overview
6.11.3 Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2024-2024)
6.11.4 Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
6.11.5 Guangzhou Nuocheng Biological Products Co., Ltd Recent Developments/Updates
6.12 Ningbo Rongan Biopharmaceutical Co., Ltd
6.12.1 Ningbo Rongan Biopharmaceutical Co., Ltd Corporation Information
6.12.2 Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Description and Business Overview
6.12.3 Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2024-2024)
6.12.4 Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
6.12.5 Ningbo Rongan Biopharmaceutical Co., Ltd Recent Developments/Updates
6.13 Shandong Yidu Biotechnology Co., Ltd
6.13.1 Shandong Yidu Biotechnology Co., Ltd Corporation Information
6.13.2 Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Description and Business Overview
6.13.3 Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2024-2024)
6.13.4 Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
6.13.5 Shandong Yidu Biotechnology Co., Ltd Recent Developments/Updates
6.14 Chengdu Kanghua Biological Products Co., Ltd
6.14.1 Chengdu Kanghua Biological Products Co., Ltd Corporation Information
6.14.2 Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Description and Business Overview
6.14.3 Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2024-2024)
6.14.4 Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
6.14.5 Chengdu Kanghua Biological Products Co., Ltd Recent Developments/Updates
6.15 Wuhan Institute of Biological Products Co., Ltd
6.15.1 Wuhan Institute of Biological Products Co., Ltd Corporation Information
6.15.2 Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Description and Business Overview
6.15.3 Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2024-2024)
6.15.4 Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
6.15.5 Wuhan Institute of Biological Products Co., Ltd Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Attenuated Vaccine for Human Rabies Industry Chain Analysis
7.2 Attenuated Vaccine for Human Rabies Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Attenuated Vaccine for Human Rabies Production Mode & Process
7.4 Attenuated Vaccine for Human Rabies Sales and Marketing
7.4.1 Attenuated Vaccine for Human Rabies Sales Channels
7.4.2 Attenuated Vaccine for Human Rabies Distributors
7.5 Attenuated Vaccine for Human Rabies Customers
8 Attenuated Vaccine for Human Rabies Market Dynamics
8.1 Attenuated Vaccine for Human Rabies Industry Trends
8.2 Attenuated Vaccine for Human Rabies Market Drivers
8.3 Attenuated Vaccine for Human Rabies Market Challenges
8.4 Attenuated Vaccine for Human Rabies Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Attenuated Vaccine for Human Rabies Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Attenuated Vaccine for Human Rabies Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Attenuated Vaccine for Human Rabies Market Competitive Situation by Manufacturers in 2022
Table 4. Global Attenuated Vaccine for Human Rabies Sales (K Units) of Key Manufacturers (2024-2024)
Table 5. Global Attenuated Vaccine for Human Rabies Sales Market Share by Manufacturers (2024-2024)
Table 6. Global Attenuated Vaccine for Human Rabies Revenue (US$ Million) by Manufacturers (2024-2024)
Table 7. Global Attenuated Vaccine for Human Rabies Revenue Share by Manufacturers (2024-2024)
Table 8. Global Market Attenuated Vaccine for Human Rabies Average Price (US$/Unit) of Key Manufacturers (2024-2024)
Table 9. Global Key Players of Attenuated Vaccine for Human Rabies, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Attenuated Vaccine for Human Rabies, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Attenuated Vaccine for Human Rabies, Product Type & Application
Table 12. Global Key Manufacturers of Attenuated Vaccine for Human Rabies, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Attenuated Vaccine for Human Rabies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Attenuated Vaccine for Human Rabies as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Attenuated Vaccine for Human Rabies Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Table 17. Global Attenuated Vaccine for Human Rabies Sales by Region (2024-2024) & (K Units)
Table 18. Global Attenuated Vaccine for Human Rabies Sales Market Share by Region (2024-2024)
Table 19. Global Attenuated Vaccine for Human Rabies Sales by Region (2024-2034) & (K Units)
Table 20. Global Attenuated Vaccine for Human Rabies Sales Market Share by Region (2024-2034)
Table 21. Global Attenuated Vaccine for Human Rabies Revenue by Region (2024-2024) & (US$ Million)
Table 22. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Region (2024-2024)
Table 23. Global Attenuated Vaccine for Human Rabies Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Region (2024-2034)
Table 25. North America Attenuated Vaccine for Human Rabies Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 26. North America Attenuated Vaccine for Human Rabies Sales by Country (2024-2024) & (K Units)
Table 27. North America Attenuated Vaccine for Human Rabies Sales by Country (2024-2034) & (K Units)
Table 28. North America Attenuated Vaccine for Human Rabies Revenue by Country (2024-2024) & (US$ Million)
Table 29. North America Attenuated Vaccine for Human Rabies Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe Attenuated Vaccine for Human Rabies Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 31. Europe Attenuated Vaccine for Human Rabies Sales by Country (2024-2024) & (K Units)
Table 32. Europe Attenuated Vaccine for Human Rabies Sales by Country (2024-2034) & (K Units)
Table 33. Europe Attenuated Vaccine for Human Rabies Revenue by Country (2024-2024) & (US$ Million)
Table 34. Europe Attenuated Vaccine for Human Rabies Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific Attenuated Vaccine for Human Rabies Revenue by Region: 2024 VS 2022 VS 2034 (US$ Million)
Table 36. Asia Pacific Attenuated Vaccine for Human Rabies Sales by Region (2024-2024) & (K Units)
Table 37. Asia Pacific Attenuated Vaccine for Human Rabies Sales by Region (2024-2034) & (K Units)
Table 38. Asia Pacific Attenuated Vaccine for Human Rabies Revenue by Region (2024-2024) & (US$ Million)
Table 39. Asia Pacific Attenuated Vaccine for Human Rabies Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America Attenuated Vaccine for Human Rabies Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 41. Latin America Attenuated Vaccine for Human Rabies Sales by Country (2024-2024) & (K Units)
Table 42. Latin America Attenuated Vaccine for Human Rabies Sales by Country (2024-2034) & (K Units)
Table 43. Latin America Attenuated Vaccine for Human Rabies Revenue by Country (2024-2024) & (US$ Million)
Table 44. Latin America Attenuated Vaccine for Human Rabies Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa Attenuated Vaccine for Human Rabies Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 46. Middle East & Africa Attenuated Vaccine for Human Rabies Sales by Country (2024-2024) & (K Units)
Table 47. Middle East & Africa Attenuated Vaccine for Human Rabies Sales by Country (2024-2034) & (K Units)
Table 48. Middle East & Africa Attenuated Vaccine for Human Rabies Revenue by Country (2024-2024) & (US$ Million)
Table 49. Middle East & Africa Attenuated Vaccine for Human Rabies Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global Attenuated Vaccine for Human Rabies Sales (K Units) by Type (2024-2024)
Table 51. Global Attenuated Vaccine for Human Rabies Sales (K Units) by Type (2024-2034)
Table 52. Global Attenuated Vaccine for Human Rabies Sales Market Share by Type (2024-2024)
Table 53. Global Attenuated Vaccine for Human Rabies Sales Market Share by Type (2024-2034)
Table 54. Global Attenuated Vaccine for Human Rabies Revenue (US$ Million) by Type (2024-2024)
Table 55. Global Attenuated Vaccine for Human Rabies Revenue (US$ Million) by Type (2024-2034)
Table 56. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Type (2024-2024)
Table 57. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Type (2024-2034)
Table 58. Global Attenuated Vaccine for Human Rabies Price (US$/Unit) by Type (2024-2024)
Table 59. Global Attenuated Vaccine for Human Rabies Price (US$/Unit) by Type (2024-2034)
Table 60. Global Attenuated Vaccine for Human Rabies Sales (K Units) by Application (2024-2024)
Table 61. Global Attenuated Vaccine for Human Rabies Sales (K Units) by Application (2024-2034)
Table 62. Global Attenuated Vaccine for Human Rabies Sales Market Share by Application (2024-2024)
Table 63. Global Attenuated Vaccine for Human Rabies Sales Market Share by Application (2024-2034)
Table 64. Global Attenuated Vaccine for Human Rabies Revenue (US$ Million) by Application (2024-2024)
Table 65. Global Attenuated Vaccine for Human Rabies Revenue (US$ Million) by Application (2024-2034)
Table 66. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Application (2024-2024)
Table 67. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Application (2024-2034)
Table 68. Global Attenuated Vaccine for Human Rabies Price (US$/Unit) by Application (2024-2024)
Table 69. Global Attenuated Vaccine for Human Rabies Price (US$/Unit) by Application (2024-2034)
Table 70. AstraZeneca Corporation Information
Table 71. AstraZeneca Description and Business Overview
Table 72. AstraZeneca Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 73. AstraZeneca Attenuated Vaccine for Human Rabies Product
Table 74. AstraZeneca Recent Developments/Updates
Table 75. GlaxoSmithKline Corporation Information
Table 76. GlaxoSmithKline Description and Business Overview
Table 77. GlaxoSmithKline Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 78. GlaxoSmithKline Attenuated Vaccine for Human Rabies Product
Table 79. GlaxoSmithKline Recent Developments/Updates
Table 80. Merck & Co Inc Corporation Information
Table 81. Merck & Co Inc Description and Business Overview
Table 82. Merck & Co Inc Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 83. Merck & Co Inc Attenuated Vaccine for Human Rabies Product
Table 84. Merck & Co Inc Recent Developments/Updates
Table 85. Sanofi Pasteur, Inc Corporation Information
Table 86. Sanofi Pasteur, Inc Description and Business Overview
Table 87. Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 88. Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Product
Table 89. Sanofi Pasteur, Inc Recent Developments/Updates
Table 90. Cadila Pharmaceuticals Ltd Corporation Information
Table 91. Cadila Pharmaceuticals Ltd Description and Business Overview
Table 92. Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 93. Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Product
Table 94. Cadila Pharmaceuticals Ltd Recent Developments/Updates
Table 95. Novartis AG Corporation Information
Table 96. Novartis AG Description and Business Overview
Table 97. Novartis AG Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 98. Novartis AG Attenuated Vaccine for Human Rabies Product
Table 99. Novartis AG Recent Developments/Updates
Table 100. Pfizer Inc Corporation Information
Table 101. Pfizer Inc Description and Business Overview
Table 102. Pfizer Inc Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 103. Pfizer Inc Attenuated Vaccine for Human Rabies Product
Table 104. Pfizer Inc Recent Developments/Updates
Table 105. Liaoning Yisheng Biopharmaceutical Co., Ltd Corporation Information
Table 106. Liaoning Yisheng Biopharmaceutical Co., Ltd Description and Business Overview
Table 107. Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 108. Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product
Table 109. Liaoning Yisheng Biopharmaceutical Co., Ltd Recent Developments/Updates
Table 110. Lanzhou Institute of Biological Products Co., Ltd Corporation Information
Table 111. Lanzhou Institute of Biological Products Co., Ltd Description and Business Overview
Table 112. Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 113. Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product
Table 114. Lanzhou Institute of Biological Products Co., Ltd Recent Developments/Updates
Table 115. Changchun Zhuoyi Biological Co., Ltd Corporation Information
Table 116. Changchun Zhuoyi Biological Co., Ltd Description and Business Overview
Table 117. Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 118. Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Product
Table 119. Changchun Zhuoyi Biological Co., Ltd Recent Developments/Updates
Table 120. Guangzhou Nuocheng Biological Products Co., Ltd Corporation Information
Table 121. Guangzhou Nuocheng Biological Products Co., Ltd Description and Business Overview
Table 122. Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 123. Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product
Table 124. Guangzhou Nuocheng Biological Products Co., Ltd Recent Developments/Updates
Table 125. Ningbo Rongan Biopharmaceutical Co., Ltd Corporation Information
Table 126. Ningbo Rongan Biopharmaceutical Co., Ltd Description and Business Overview
Table 127. Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 128. Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product
Table 129. Ningbo Rongan Biopharmaceutical Co., Ltd Recent Developments/Updates
Table 130. Shandong Yidu Biotechnology Co., Ltd Corporation Information
Table 131. Shandong Yidu Biotechnology Co., Ltd Description and Business Overview
Table 132. Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 133. Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Product
Table 134. Shandong Yidu Biotechnology Co., Ltd Recent Developments/Updates
Table 135. Chengdu Kanghua Biological Products Co., Ltd Corporation Information
Table 136. Chengdu Kanghua Biological Products Co., Ltd Description and Business Overview
Table 137. Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 138. Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product
Table 139. Chengdu Kanghua Biological Products Co., Ltd Recent Developments/Updates
Table 140. Wuhan Institute of Biological Products Co., Ltd Corporation Information
Table 141. Wuhan Institute of Biological Products Co., Ltd Description and Business Overview
Table 142. Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 143. Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product
Table 144. Wuhan Institute of Biological Products Co., Ltd Recent Developments/Updates
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. Attenuated Vaccine for Human Rabies Distributors List
Table 148. Attenuated Vaccine for Human Rabies Customers List
Table 149. Attenuated Vaccine for Human Rabies Market Trends
Table 150. Attenuated Vaccine for Human Rabies Market Drivers
Table 151. Attenuated Vaccine for Human Rabies Market Challenges
Table 152. Attenuated Vaccine for Human Rabies Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Attenuated Vaccine for Human Rabies
Figure 2. Global Attenuated Vaccine for Human Rabies Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Attenuated Vaccine for Human Rabies Market Share by Type in 2022 & 2034
Figure 4. Vero Cell Product Picture
Figure 5. Human Diploid Cell Product Picture
Figure 6. Global Attenuated Vaccine for Human Rabies Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 7. Global Attenuated Vaccine for Human Rabies Market Share by Application in 2022 & 2034
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Global Attenuated Vaccine for Human Rabies Revenue, (US$ Million), 2024 VS 2022 VS 2034
Figure 11. Global Attenuated Vaccine for Human Rabies Market Size (2024-2034) & (US$ Million)
Figure 12. Global Attenuated Vaccine for Human Rabies Sales (2024-2034) & (K Units)
Figure 13. Global Attenuated Vaccine for Human Rabies Average Price (US$/Unit) & (2024-2034)
Figure 14. Attenuated Vaccine for Human Rabies Report Years Considered
Figure 15. Attenuated Vaccine for Human Rabies Sales Share by Manufacturers in 2022
Figure 16. Global Attenuated Vaccine for Human Rabies Revenue Share by Manufacturers in 2022
Figure 17. The Global 5 and 10 Largest Attenuated Vaccine for Human Rabies Players: Market Share by Revenue in 2022
Figure 18. Attenuated Vaccine for Human Rabies Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024 VS 2022
Figure 19. Global Attenuated Vaccine for Human Rabies Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Figure 20. North America Attenuated Vaccine for Human Rabies Sales Market Share by Country (2024-2034)
Figure 21. North America Attenuated Vaccine for Human Rabies Revenue Market Share by Country (2024-2034)
Figure 22. United States Attenuated Vaccine for Human Rabies Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 23. Canada Attenuated Vaccine for Human Rabies Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 24. Europe Attenuated Vaccine for Human Rabies Sales Market Share by Country (2024-2034)
Figure 25. Europe Attenuated Vaccine for Human Rabies Revenue Market Share by Country (2024-2034)
Figure 26. Germany Attenuated Vaccine for Human Rabies Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 27. France Attenuated Vaccine for Human Rabies Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 28. U.K. Attenuated Vaccine for Human Rabies Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 29. Italy Attenuated Vaccine for Human Rabies Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 30. Russia Attenuated Vaccine for Human Rabies Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 31. Asia Pacific Attenuated Vaccine for Human Rabies Sales Market Share by Region (2024-2034)
Figure 32. Asia Pacific Attenuated Vaccine for Human Rabies Revenue Market Share by Region (2024-2034)
Figure 33. China Attenuated Vaccine for Human Rabies Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 34. Japan Attenuated Vaccine for Human Rabies Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 35. South Korea Attenuated Vaccine for Human Rabies Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 36. India Attenuated Vaccine for Human Rabies Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 37. Australia Attenuated Vaccine for Human Rabies Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 38. China Taiwan Attenuated Vaccine for Human Rabies Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 39. Southeast Asia Attenuated Vaccine for Human Rabies Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 40. Latin America Attenuated Vaccine for Human Rabies Sales Market Share by Country (2024-2034)
Figure 41. Latin America Attenuated Vaccine for Human Rabies Revenue Market Share by Country (2024-2034)
Figure 42. Mexico Attenuated Vaccine for Human Rabies Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 43. Brazil Attenuated Vaccine for Human Rabies Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 44. Argentina Attenuated Vaccine for Human Rabies Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 45. Middle East & Africa Attenuated Vaccine for Human Rabies Sales Market Share by Country (2024-2034)
Figure 46. Middle East & Africa Attenuated Vaccine for Human Rabies Revenue Market Share by Country (2024-2034)
Figure 47. Turkey Attenuated Vaccine for Human Rabies Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 48. Saudi Arabia Attenuated Vaccine for Human Rabies Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 49. UAE Attenuated Vaccine for Human Rabies Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 50. Global Sales Market Share of Attenuated Vaccine for Human Rabies by Type (2024-2034)
Figure 51. Global Revenue Market Share of Attenuated Vaccine for Human Rabies by Type (2024-2034)
Figure 52. Global Attenuated Vaccine for Human Rabies Price (US$/Unit) by Type (2024-2034)
Figure 53. Global Sales Market Share of Attenuated Vaccine for Human Rabies by Application (2024-2034)
Figure 54. Global Revenue Market Share of Attenuated Vaccine for Human Rabies by Application (2024-2034)
Figure 55. Global Attenuated Vaccine for Human Rabies Price (US$/Unit) by Application (2024-2034)
Figure 56. Attenuated Vaccine for Human Rabies Value Chain
Figure 57. Attenuated Vaccine for Human Rabies Production Process
Figure 58. Channels of Distribution (Direct Vs Distribution)
Figure 59. Distributors Profiles
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed